Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 659 | 140 | 504 |
| Samples | 614 | 131 | 473 |
| Peptides | 454 | 78 | 384 |
Function
GPR149 · G protein-coupled receptor 149
This gene encodes a seven-transmembrane G protein coupled receptor (GPCR) class A family member. Although categorized as a class A GPCR, the encoded protein lacks the first two charged amino acids of the highly conserved Asp-Arg-Tyr (DRY) motif found in the third transmembrane helix of class A receptors which is important for efficient G protein-coupled signal transduction. Mice with a knockout of the orthologous gene are viable and have normal maturation of the ovarian follicle, but show enhanced fertility and ovulation. All GPCRs have a common structural architecture consisting of seven transmembrane alpha-helices interconnected by three extracellular and three intracellular loops. A general feature of GPCR signaling is agonist-induced conformational changes in the receptor, leading to activation of the heterotrimeric G proteins, which consist of the guanine nucleotide-binding G-alpha subunit and the dimeric G-beta-gamma subunits. The activated G proteins then bind to and activate numerous downstream effector proteins, which generate second messengers that mediate a broad range of cellular and physiological processes. [provided by RefSeq, Jul 2017].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000389740 | Q86SP6 | 659 | 454 |
Gene Properties
Recurrent Mutations
All 454 amino-acid changes on canonical ENST00000389740 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GPR149 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GPR149 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 11/40 28% | 0/0 0% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 25/612 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Colorectal Carcinoma | 23/143 16% | 90/3239 3% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Melanoma | 7/210 3% | 57/1899 3% |
| Non-Small Cell Lung Carcinoma | 13/304 4% | 32/1390 2% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 22/810 3% |
| Neuroendocrine Tumour | 14/154 9% | 4/577 1% |
| Gastric Carcinoma | 2/74 3% | 38/1809 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Plasma Cell Myeloma | 2/44 5% | 3/305 1% |
| Cervical Carcinoma | 0/35 0% | 6/422 1% |
| Other Sarcomas | 3/69 4% | 7/699 1% |
| Ovarian Carcinoma | 3/109 3% | 11/998 1% |
| Biliary Tract Carcinoma | 3/54 6% | 9/950 1% |
| Other Solid Cancers | 0/94 0% | 19/1515 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 9/752 1% |
| Bladder Carcinoma | 3/58 5% | 9/956 1% |
| Non-Cancerous | 3/104 3% | 6/830 1% |
| Ewings Sarcoma | 2/63 3% | 1/262 0% |
| Mesothelioma | 0/62 0% | 2/165 1% |
| Head and Neck Carcinoma | 3/85 4% | 11/1574 1% |
| Hepatocellular Carcinoma | 1/46 2% | 18/2210 1% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 16/2550 1% |
| Glioma | 2/52 4% | 12/2127 1% |
| Esophageal Carcinoma | 1/23 4% | 4/769 1% |
Mutation Distribution
Where GPR149 is mutated · all tissues, split by cell line vs tissue
How many mutations in GPR149 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 18 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 659 mutations in GPR149
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|